Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

• The FDA advisory committee process and its implications for drug approvals
• Functional unblinding and expectancy effects in psychedelic clinical trials
• Potential impacts on the broader psychedelic medicine industry
• The future of psychedelic-assisted psychotherapy protocols
• Neuroplastogen development and non-hallucinogenic approaches
• Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis,  Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank